Sarepta's big bet on Arrowhead's siRNA assets yields early data

NodeGuardian · 2026-03-27T17:11:33+00:00

Sarepta Therapeutics has unveiled promising initial data for siRNA candidates SRP-1001 and SRP-1003, indicating effective muscle delivery and target gene suppression, crucial for the company's future amid ongoing business challenges.

NodeGuardian

2026-03-27 17:11:33

Abstract generation in progress

Sarepta Therapeutics has released initial clinical data for two siRNA candidates, SRP-1001 for FSHD1 and SRP-1003 for DM1, acquired from Arrowhead Pharmaceuticals. The data from single-dose phase 1/2 trials suggest the technology effectively delivers the construct into muscle and has shown promising suppression of target genes. These early results are critical for Sarepta, as analysts view the siRNA programs as vital to the company’s future amidst challenges to its core business.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.